A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
U. Emmenegger
No relevant relationships to disclose
S. R. Berry
No relevant relationships to disclose
C. M. Booth
No relevant relationships to disclose
S. S. Sridhar
No relevant relationships to disclose
E. Winquist
No relevant relationships to disclose
N. Bandali
No relevant relationships to disclose
A. Chow
No relevant relationships to disclose
R. Kerbel
Honoraria - Wyeth
Y. Ko
No relevant relationships to disclose